Objective: Tissue-engineered vascular grafts containing adipose-derived mesenchymal stem cells offer an alternative to small-diameter vascular grafts currently used in cardiac and lower-extremity revascularization procedures. Adiposederived, mesenchymal stem cell-infused, tissue-engineered vascular grafts have been shown to promote remodeling and vascular homeostasis in vivo and offer a possible treatment solution for those with cardiovascular disease. Unfortunately, the time needed to cultivate adipose-derived mesenchymal stem cells remains a large hurdle for tissue-engineered vascular grafts as a treatment option. The purpose of this study was to determine if stromal vascular fraction (known to contain progenitor cells) seeded tissue-engineered vascular grafts would remain patent in vivo and remodel, allowing for a ''same-day'' process for tissue-engineered vascular graft fabrication and implantation.
Perspective
The current field of TEVG technology still requires long fabrication times and faces regulatory hurdles. We now present work using stem cells directly sourced from human lipoaspirates for TEVG fabrication in an approach that allows cell harvest, seeding, and implantation within a 24-hour period, which is a critical step toward clinical translation.
See Editorial Commentary page 1823.
Cardiovascular disease remains the leading cause of death in the United States, significantly contributing to morbidity and mortality. [1] [2] [3] Treatment costs are expected to reach more than $918 billion per year by 2020, making it the highest total healthcare expenditure in the United States. 4 Commonly
From the Departments of a Surgery, performed procedures in the treatment of cardiovascular disease include bypass graft replacement using native autologous vessels comprising the thoracic and radial arteries and saphenous vein, 2, 5, 6 with coronary artery bypass accounting for approximately 400,000 operations performed annually in the United States as of 2016. 7 However, use of autologous vessels comes with inherent drawbacks, such as size and mechanical mismatch, availability, and complications associated with morbidity from surgical harvest. [8] [9] [10] [11] In addition, synthetic grafts fail because of acute thrombosis at diameters less than 6 mm. [12] [13] [14] To overcome these limitations, small-diameter (<6 mm) tissue-engineered vascular grafts (TEVGs) have been developed that resist thrombosis and intimal hyperplasia. [15] [16] [17] [18] [19] [20] [21] Much of this work uses cell-based TEVGs. However, such cell-based TEVGs come with the limitations that cells often require time to expand before TEVG fabrication, and cell seeding on the TEVG scaffold often requires lengthy bioreactor culture before implantation. Furthermore, cell culture and expansion limit clinical applicability because of regulatory concerns set by the Food and Drug Administration, which recommends the use of fresh cells with minimized time between isolation and implantation. 22 A noncultured, progenitor cell-rich population known as the stromal vascular fraction (SVF) could circumvent these concerns about cell-based TEVGs. In a recent study by our group, scaffolds seeded with SVF and exposed to a 48-hour dynamic culture period produced TEVGs in vivo that were comparable to TEVGs produced using cultured adiposederived mesenchymal stem cells (ADMSCs). 6 However, although the culture period and time of fabrication were greatly reduced in this study, it still used an in vitro culture step.
We hypothesized that the removal of any and all culture steps, including the 48-hour dynamic bioreactor culture period in our previously reported SVF seeded TEVG model, would not affect productive in vivo remodeling, allowing for a ''same-day'' process for TEVG fabrication and implantation (Video 1). To test this hypothesis, a smallscale proof of concept study was conducted to demonstrate the ability for a completely noncultured cell population seeded onto an elastomeric scaffold and immediately placed as an interpositional graft in the abdominal aorta to remodel into a functional TEVG. To relate this study to earlier work in our laboratory, we compared the phenotypic diversity of cells within SVF seeded directly into our TEVGs for immediate implantation with that within our TEVGs after a 48-hour dynamic culture period, as well as with that of SVF that is culture expanded before seeding onto our TEVGs. Our results demonstrate that TEVGs manufactured in a single day perform similar to cultured TEVGs or TEVGs seeded with culture-expanded cells, representing a significant advancement in TEVG clinical translation.
MATERIALS AND METHODS Patient Selection and Stromal Vascular Fraction Isolation
SVF was obtained from the discarded waste adipose tissue of nondiabetic female human adults, 45 years of age or younger, undergoing elective standard of care liposuction, abdominoplasty, or panniculectomy procedures. Tissue was transferred to the research team through an honest broker under University of Pittsburgh Institutional Review Board exempt protocol #0511186. 23, 24 Because this was an exempt protocol and no identifiable information was available to the research staff, informed consent was not obtained. Patient information was limited to age in years, gender, body mass index, and diabetic status.
SVF was freshly isolated using previously described methods. 25, 26 Briefly, adipose tissue ($250 mL per patient) was cut into approximately 10-mL portions that were each placed into separate 50-mL conical tubes. Each piece was minced and added to a collagenase solution, Hanks' Balanced Salt Solution (Invitrogen, Carlsbad, Calif), containing 3.5% bovine serum albumin (Millipore, Charlottesville, Va) and 1 mg/mL collagenase type II (Worthington, Lakewood, NJ). 26 Tubes were then incubated at 37 C with agitation for approximately 1 hour. Digested tissue was filtered through successive 425-and 180-mm sieves (WS Tyler, Mentor, Ohio) to remove undigested pieces and then centrifuged at 1000 rpm for 10 minutes at ambient temperature. After centrifugation, the cell pellet was resuspended in an NH 4 Cl-based buffer (Beckman Coulter, Miami, Fla; Cat No. IM3630d) to lyse red blood cells. The resulting cell suspension was filtered once more through a 180-mm sieve and centrifuged (1000 rpm, 10 minutes, ambient temperature). The resulting pellet, termed ''SVF,'' was resuspended in Hanks' Balanced VIDEO 1. Video walkthrough of the ''same-day'' process of vascular graft fabrication and implantation explored in this article. 
Scaffold Fabrication
Scaffolds used in this study were fabricated out of poly(ester urethane) urea (PEUU), which is biodegradable and elastomeric. Scaffolds were bilayered, tubular, and approximately 1 cm long, and had an approximately 1.3-mm inner diameter to approximate the shape and size of a rat infrarenal abdominal aorta. Scaffolds were manufactured and used as described previously. 16, 17, 27, 28 Briefly, PEUU polymer was used to fabricate both layers of the scaffold. The porous inner layer of the scaffold was created using thermally induced phase separation (TIPS) in a tubular mold. The TIPS layer was then coated by electrospinning an additional layer of PEUU for mechanical stability. This scaffold has already shown efficacy in the TEVG context using multiple cell types. 6, 17, 19, [27] [28] [29] 
Cell Culture and Stromal Vascular Fraction Expansion for Phenotypic Analysis
A fraction of SVF was expanded in cell culture using defined culture media (1:1 Dulbecco's modified Eagle's medium #11965; Gibco, Waltham, Mass) with Dulbecco's modified Eagle's medium/F12 (#113300; Gibco) and 10% fetal bovine serum (#S11550; Atlanta Biologicals, Flowery Branch, Ga), antibiotics (1% penicillin/streptomycin, 0.5% Fungizone, 0.1% gentamycin; all from Gibco), and 10 mL/L dexamethasone mixed with 25% Preadipocyte Growth Medium (#C-27410, #C-39425; PromoCell, Heidelberg, Germany). Upon reaching 80% confluency, the cells were removed from the plate by trypsinization and termed ''passage 0 ADMSC.'' These cells were then plated for additional expansion up to passage 4 using the same protocol or used directly for seeding experiments.
Scaffold Seeding and Incubation
Scaffolds were seeded with SVF or passage 0 to 4 ADMSC using a customized rotational vacuum seeding device as described and used previously. 19, [29] [30] [31] Briefly, the scaffolds were mounted within the device, and the cell suspension was infused with vacuum and rotation (flow rate of 1 mL/min, vacuum pressure of À120 mm Hg, and rotation speed of 15 rpm). Each scaffold was seeded with approximately 3 million SVF cells.
After seeding, the constructs were placed in defined culture media (see ''Cell Culture and Stromal Vascular Fraction Expansion for Phenotypic Analysis'') for transport and immediate implantation (see ''Aortic Implantation of Seeded Scaffolds'') or given 4 hours incubation for phenotypic analysis, allowing the cells to adhere to the scaffold under static conditions. At this point, constructs were fixed or dynamically cultured for an additional 48 hours. As previously described, dynamic culture entailed suspension in a 500-mL spinner flask (Kontes #Cytostir 882911-0250) (100 mL of defined culture media, rotation speed 15 rpm).
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Phenotypic Analysis of Seeded Scaffolds
Seeded constructs used for phenotypic analysis were fixed in 4% paraformaldehyde, washed, placed in a 30% sucrose solution for 30 minutes, and frozen at À20 C. Frozen seeded constructs were then sectioned using a cryostat at a thickness of 10 mm onto gelatin-coated slides. To determine the SVF cell populations adhering to the PEUU scaffolds, immunofluorescent chemistry (IFC) was performed. Sections of the seeded constructs were permeabilized using a 0.1% Triton solution, and 5% goat serum was used for blocking. Sections were incubated with 1:100 dilutions of rabbit anti-human CD90 (ab133350, Abcam, Cambridge, UK), rabbit anti-human CD31 (ab28364, Abcam), or rabbit anti-human CD34 (ab81289, Abcam) to evaluate the presence of mesenchymal stem cell, endothelial cell, or endothelial progenitor cell populations, respectively. Additional IFC for SVF markers CD14, CD45, and CD105 was performed ( Figure E1 ). All IFC staining included a primary delete for a negative control and an additional isotype control (ab172730, Abcam). Seeded constructs were then incubated with 1:1000 dilutions of FITC-conjugated goat anti-rabbit immunoglobulin (Ig)-G secondary antibody (611-1202, Rockland, Inc, Pottstown, Pa) and then counterstained with DAPI (B2883, Sigma-Aldrich, St Louis, Mo) to mark cell nuclei. Imaging was conducted on a Nikon Eclipse 90i microscope (Nikon, Tokyo, Japan).
Cell populations were quantified by calculating the ratio between cells exhibiting each specific cell marker (CD90, CD31, and CD34) and the total cell count as established by evaluating the DAPI stained nuclei; a custom ImageJ macro was built for this purpose (for greater detail, see Supplemental Material: ImageJ Macro Analysis).
Aortic Implantation of Seeded Scaffolds
All animal procedures were performed under a protocol approved by the University of Pittsburgh Institutional Animal Care and Use Committee. Seeded scaffolds were surgically implanted as abdominal aortic interpositional grafts in Lewis rats as described previously. 17, 27, 28 Briefly, rats were anesthetized using ketamine (30 mg/kg) and placed in a supine position and kept under sedation for the duration of the surgery using nose cone administration of isoflurane (induction [2%-5%] and maintenance [0.25%-4%] 1.5 L/min in oxygen). An incision was made in the abdominal wall, and the infrarenal abdominal aorta was exposed through blunt dissection. Microclamps were applied to the aorta, which was then bisected, upon which a 1-cm seeded construct was placed interpositionally and sutured with 10-0 Prolene (Ethicon, Somerville, NJ) ( Figure E2 ). After the graft was secured, the clamps were released and the patency was verified by observation of the distal pulse pressure. The animals were then closed with 3-0 polyglactin sutures (McKesson, Richmond, Va). Buprenorphine hydrochloride was administered postoperatively every 12 hours for the first 72 hours, and animals were maintained on an anticoagulant (dipyridamole, aspirin) schedule for 4 weeks, as previously described. 16 Implanted scaffolds were allowed to remodel for 8 weeks to allow enough time for remodeling and neotissue formation to occur as previously observed. 6, 16, 29, 30 Rats were then killed using isoflurane (induction [2%-5%] 1.5 L/min oxygen) and a single intracardiac injection of heparin/KCl. The descending aorta proximal to the TEVG was catheterized and injected with x-ray contrast agent for imaging, and an angiography was performed to determine in vivo patency. The TEVG and adjacent aortic tissue were excised for gross inspection and further analysis.
Immunofluorescent and Histologic Evaluation
Explanted TEVGs were fixed in 4% paraformaldehyde before frozen sectioning or paraffin embedding. Frozen sectioning was performed as described earlier using fluorescein isothiocyanate (FITC)-conjugated mouse anti-von Willebrand factor (vWF -1:250; V2700-07, US Biological, Salem, Mass) and mouse anti-smooth muscle a-actin (aSMA) (A5228, Sigma-Aldrich) along with a TRITC conjugated anti-mouse IgG secondary antibody (ab6786, Abcam). The presence of any remaining implanted cells was also determined using IFC for rabbit anti-human CD90 (ab133350, Abcam) and human nuclear antigen (MAB1281, MEMD, Millipore) with FITC-conjugated goat anti-rabbit IgG secondary antibody (611-1202, Rockland Inc) and counterstained with DAPI (B2883, Sigma-Aldrich) to mark cell nuclei.
Histology was performed on paraffin-embedded sections of both explanted TEVGs and native rat aorta proximal to the anastomosis using the Histology Core at the McGowan Institute for Regenerative Medicine. Sections were stained for Verhoeff van Gieson staining to indicate elastin fibers and Masson's trichrome to indicate collagen and other vascular components.
Statistical Analysis
A 2-way analysis of variance was performed on the phenotypic analysis data using SPSS software (IBM, Armonk, New York, NY) between the different cell markers and each passage of cells. A Bonferroni confidence interval adjustment was made, and pairwise comparisons were made post hoc. In addition, a paired Student t test was used to evaluate statistical differences in cell markers between immediate and 48-hour cultured constructs.
RESULTS
Phenotypic Analysis of Stromal Vascular Fraction and Passaged Adipose-Derived Mesenchymal Stem Cells
SVF was gathered from 6 different subjects at the Adipose Stem Cell Research Laboratory -University of Pittsburgh (available patient information provided in Table 1 ). IFC analysis of the seeded SVF/ADMSC phenotypes showed a distinct shift with increasing passage (Figure 1) . Specifically, scaffolds seeded with culture expanded cells were found to have an approximately 4-fold increase in CD90 positive staining, whereas the percentage of cells positive for CD31 and CD34 became undetectable by passage 4 (P ¼ .004).
Additional evaluations were made comparing scaffolds seeded with fresh, uncultured SVF that were fixed immediately after seeding versus scaffolds that had 48 hours of dynamic culture before being fixed. Adherent cells in constructs seeded with fresh, uncultured SVF displayed markers for CD90, CD31, and CD34 in varying amounts with CD31 positive cells significantly higher than CD90 positive cells in the fresh SVF (P ¼ .023). Additional IFC analysis comparing the fresh, uncultured SVF found no difference in CD marker expression between constructs given only a brief time for cells to adhere to the scaffold (to compare with constructs used for implantation) and constructs given a 48-hour dynamic culture period (the standard culture used in previous studies 6, 16, 30 ) (Figure 2 ).
''Same-Day'' Tissue-Engineered Vascular Graft Implantation and Remodeling A total of 7 ''same-day'' implantation procedures, from 4 different SVF collections, were performed for this study, with most SVF harvest procedures resulting in 2 implanted scaffolds each (Table 1) . Patency was observed in 5 of the 7 TEVG explants through angiography (Figure 3, A) and gross inspection, which classified explants as fully remodeled (Figure 3 (Table 1) . Of the 2 TEVGs that were occluded, intimal hyperplasia was observed at both the proximal and distal anastomoses. No thrombus was found within either of the partially remodeled grafts or the occluded grafts, suggesting that blood was able to pass freely though the conduit before the anastomotic hyperplasia emerged.
Broadly, patency corresponded with a layer of neotissue that formed on top of the TIPS layer, surrounding an open lumen. Further IFC analysis of the patent grafts revealed extensive vWF staining along the luminal edge in a continuous manner, indicating the presence of an endothelial lining and seemingly organized aSMA staining within the neotissue in 3 of the fully remodeled patent grafts ( Figure 4, A and B) . The other 2 partially remodeled grafts lacked an organized luminal lining or vascular-like tissue formation ( Figure 4 , C and D) compared with a native rat aorta ( Figure 4, E and F) . Further histologic analysis of the fully remodeled TEVGs using Verhoeff van Gieson staining also revealed elastin fibers within the neotissue especially toward the luminal edge, and Masson's trichrome staining revealed the presence of newly formed collagen ( Figure 5 ).
DISCUSSION
This study showed that adherent cells in the SVF shifted their surface markers away from endothelial and endothelial progenitor markers (CD31 and CD34) and toward expression of the ADMSC marker CD90 by passage 4. Furthermore, the adherent cells in the SVF had the same phenotypic distribution with or without the previously described 48-hour dynamic culture period. 6 Most important, removal of the 48-hour dynamic culture period (or any culture other than a brief period to allow cells to adhere to the scaffolds) and the implementation of the collection, isolation, seeding, and implantation steps within a 24-hour, ''same-day'' procedure generated a functioning TEVG. With streamlining, the entire procedure was able to be accomplished within a 12-hour period by the end of the study.
The focus of work in our laboratory, and the motivation for this study, is the generation of a TEVG within a clinically relevant time scale. Previous work by Krawiec and colleagues 16, 25 made use of cultured ADMSCs that took up to 1 month or more from collection to implantation. This waiting time between collection and implantation was able to be drastically reduced when using a noncultured cell source, but still included dynamic culture, thus limiting its clinical feasibility. When comparing the ''same-day'' procedure with that of SVF-seeded constructs given 48 hours of dynamic culture, patency rates were similar. 6 Notably, none of the ''sameday'' TEVGs failed because of thrombosis. A recent review suggests that TEVG failure due to thrombosis is caused by the graft having poor blood interaction, whereas in contrast, failure due to hyperplasia often can be attributed to conduit mismatch, surgical error, or damage to the endothelium that creates hyperplastic conditions. 2 Previously, bare PEUU scaffolds have been used with patency rates of less than 40%, 19 whereas other work in our laboratory has shown patent TEVGs can be generated using bone marrow-derived MSCs, 17 muscle-derived MSCs, 27 and pericytes 28 with varying patency rates, whereas patency rates of 100% have been achieved with ADMSCs from young, nondiabetic donors. 16 Thus, it is important to note that although only 5 of the 7 TEVGs were patent at 8 weeks, a microsurgeon highly experienced with the model would likely experience higher patency rates.
Several other groups have moved a TEVG toward clinical implementation. Shinoka 32 and Breuer have tested their technology as low-pressure conduits in large animal models and human trials, 33, 34 whereas L'Heureux and colleagues at Cytograft (Novato, Calif) developed a TEVG constructed using a cell sheet technology as an arteriovenous shunt for hemodialysis under the product name Lifeline. 35 Of note, the Lifeline technology used a patient's own fibroblasts and endothelial cells in 2 rounds of culture that took up to 7 months to complete, although newer methods have moved into human trials with devitalized scaffolds lacking an endothelium. 21 Niklason and colleagues at Humacyte (Morrisville, NC) have established the ''human acellular vessel'' line of TEVG products. 36 This TEVG is fabricated using bioreactor culture and can take 1 month to fabricate. 32 Although these TEVGs have already made it to clinical trials, the time needed for bioreactor FIGURE 2. Average cell populations for SVF constructs fixed after initial incubation and 48 hours of dynamic culture (n ¼ 6). A paired t test indicated no significant statistical difference between initial and 48-hour constructs for each of the CD90, CD31, and CD34 markers (P ¼ .63, .68, and .46, respectively). incubation, with potential cellular transformation or contamination, and an indeterminate shelf life of both the Cytograft and Humacyte TEVGs may raise some concern and possibly limit their clinical utility. 21, 36 Thus, the impetus remains for a scaffold that can be safely stored long term and then seeded and implanted as a TEVG within a single operating room.
Study Limitations
Future work will have to go beyond a preliminary study performed in an immunotolerant rat model implanted with xenogeneic human cells and move toward a more clinically relevant model. This should include a large animal model to accommodate a longer and larger caliber TEVG fabricated with autologous or allogeneic cells. Such large animal models would be able to answer critical questions, such as the robustness of host cell infiltration into a longer graft. This study, like nearly all other studies done previously using TEVGs in an animal model, 16, 37 made use of only young animals. Going forward, a more clinically relevant recipient population must be used including older animals and nonimmunotolerant hosts. It might also be valuable to examine more closely the mechanisms of remodeling and prevention of acute thrombosis of the implant. Another limitation of our study was the amount of time and effort required to manually process enough SVF cells for seeding the TEVG. However, devices and methods to more rapidly produce SVF cells in large volumes have been advancing rapidly. Devices such as the Tissuegenesis ICELLATOR (Honolulu, Hawaii), GID SVF-1 (GID Europe, London, United Kingdom), Puregraft (Puregraft, Solana Beach, Calif), and Duografter II (Proteal, Barcelona, Spain) 38 are already being used clinically and provide a feasible method to accelerate TEVG fabrication with SVF. Last, a potential limitation of implanting a construct seeded with SVF is that these cells represent a phenotypically diverse population that could differentiate in an uncontrolled manner. However, the cells are not expected to remain in the construct for long, 39 and any manipulation of the SVF (eg, purification to specific cell types) would defeat the purpose of the ''same-day'' strategy by restoring regulatory concerns. Moreover, the SVF cell population has recently been shown to have possibly better pro-remodeling effects than cultured ADMSCs, 24, 40 and thus is another important facet of this model that is of current interest for further study.
This was a small-scale feasibility study demonstrating that a culture-free, single-day process could be successful and comparable to our standard ADMSC-seeded TEVG model, with phenotypic comparisons between the 2 cell populations. The motivation behind the study-to create a ''same-day'' TEVG-moves toward a clinically relevant technology in which an off-the-shelf scaffold could be seeded and implanted within a practical timeframe. Future directions must also answer what the long-term outcomes (beyond 8 weeks) are for such technology and if there is any phenotypic difference between donor populations that might contribute or detract from overall TEVG remodeling and maturation. Even so, the ability to generate and implant a TEVG within a single day that remodels and generates a vessel-like conduit marks significant progress. Thus, the overall goal of our work toward creating a functional TEVG by removing any culture period and streamlining the process of cell population collection, fabrication and seeding, and implantation to within a ''same-day'' period was met. With this and other techniques in hand, novel grafts and methods could someday make TEVGs a clinical reality.
CONCLUSIONS
Patency of our SVF-seeded TEVGs after 8 weeks in vivo was achieved using a ''same-day'' process. The seeded SVF cell population had no phenotypic differences between those with or without a 48-hour dynamic culture period, but was significantly different from ADMSCs at passage 4. TEVGs were able to remodel in vivo with gross inspection and histology indicating neotissue formation and immunostaining for vWF and aSMA demonstrating the presence of an endothelium and smooth muscle cells, respectively. 
